Key Inclusion Criteria:~1. Meets National Institute on Aging and Alzheimer's Association Research Framework
criteria for individuals in clinical Stage 4 or 5 of the Alzheimer's continuum.~2. Evidence for AD
pathophysiology, confirmed either prior to or during screening.~3. MMSE score ≥ 16 and ≤ 27 at screening.~4.
Clinical Dementia Rating - Global Score must be 0.5, 1 or 2.~5. If receiving background AD medications, the
dosing regimen must be stable for at least 12 weeks prior to randomization. Chronic medications for conditions
other than AD (such as depression) must be prescribed at a stable dose for at least 4 weeks prior to
screening.~6. The subject has not been a cigarette smoker or chewed tobacco for at least 3 years.~7.
Availability of a study partner.~8. Individuals who have participated in a clinical study with an
investigational drug targeting the underlying AD process may be permitted to participate in this study.~9.
Completed a COVID-19 vaccine primary series (fully vaccinated) at least 2 weeks prior to randomization or had
an unambiguous COVID-19 infection diagnosed more than 3 months before the start of the Screening Period.~Key
